FRUCTOSE-1, 6 DIPHOSPHATE

1, 6 二磷酸果糖

• 批准号: 6245173
• 负责人: DAVID GREEN
• 金额: $ 1.2万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-15 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245173
• 关键词: adenosine triphosphate; blood disorder chemotherapy; clinical research; dosage; drug screening /evaluation; drug tolerance; fructose phosphate; human subject; human therapy evaluation; hypoxia; ischemia; sickle cell crisis

Fructose-1, 6 Diphosphate is anaerobically metabolized to yield 4 mol of ATP. The vasoocclusive crises of sickle cell disease are characterized by tissue ischemia due to hypoxemia. Hypoxemia promotes the change from flexible erythrocytes to rigid sickle cells and aggravates tissue ischemia. Providing energy by increasing intracellular ATP may prevent sickling and shorten crises. A dose escalation study will be performed in three stages. This pilot study should establish the tolerability of FDP and the efficacy and safety of this agent.

果糖1，6二磷酸厌氧代谢可产生4摩尔 ATP。镰状细胞疾病的血管判定危机是特征的 由于低氧血症引起的组织缺血。 低氧血症促进了从 柔性红细胞至刚性镰状细胞并加剧组织 缺血。 通过增加细胞内ATP来提供能量 恶心和缩短危机。 将进行剂量升级研究 在三个阶段。 这项试验研究应确定 FDP以及该代理的功效和安全性。